Last reviewed · How we verify
Cannabis sativa Extract
At a glance
| Generic name | Cannabis sativa Extract |
|---|---|
| Also known as | Cannabis sativa, Cannabis sativa Flowering Top, Cannabis sativa Subsp. Flowering Top Extract, Cannabis sativa Top |
| Sponsor | Roswell Park Cancer Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream (EARLY_PHASE1)
- Efficacy and Safety of VER-01 in the Treatment of Patients With Radicular Chronic Low Back Pain (PHASE3)
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Cannabis for Obesity Trial (PHASE2)
- Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC) (PHASE3)
- Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome (PHASE2, PHASE3)
- NTI164 in Autism Spectrum Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabis sativa Extract CI brief — competitive landscape report
- Cannabis sativa Extract updates RSS · CI watch RSS
- Roswell Park Cancer Institute portfolio CI